Introduction: Natural killer (NK) cells play an irreplaceable and important role as a subtype of innate immune cells in the contemporary setting of antitumor immunity.Methods: We chose a total of 1,196 samples for this analysis from the public dataset’s six separate cohorts. To identify 42 NK cell marker genes, we first carried out a thorough study of single-cell RNA sequencing data from the GSE149614 cohort of hepatocellular carcinoma (HCC).Results: Using the NK cell marker genes in the TCGA cohort, we next created a seven-gene prognostic signature, separating the patients into two categories with distinct survival patterns. This signature’s prognostic prediction ability was well verified across several validation cohorts. Patients with high scores had higher TIDE scores but lower immune cell infiltration percentages. Importantly, low-scoring patients had superior immunotherapy response and prognosis than high-scoring patients in an independent immunotherapy cohort (IMvigor210). Finally, we used CD56 and TUBA1B antibodies for immunohistochemical labeling of HCC tissue sections, and we discovered a lower number of CD56+ cells in the HCC tissue sections with high TUBA1B expression.Discussion: In summary, our research created a unique prognostic profile based on NK cell marker genes that may accurately predict how well immunotherapy would work for HCC patients.
Background and Aim: Necroptosis plays an important role in hepatocellular carcinoma (HCC) development, recurrence, and immunotherapy tolerance. We aimed to build a new prognostic necroptosis-related gene signature that could be used for survival and immunotherapy prediction in HCC patients. Methods: We found that necroptosis was associated with HCC progression and survival outcomes and was involved in the immune infiltration of HCC. Multiple bioinformatics methods including WGCNA, LASSO-Cox regression, stepwise Cox regression, and Random Forest and Boruta model analysis, were used to establish a prognostic profile related to necroptosis. The necroptosis-related gene signature was validated in ICGC and GSE14520 datasets. Results: This five-gene signature showed excellent predictive performance and was an independent risk factor for patients’ overall survival outcome in the three cohorts. Moreover, this signature was an exact predictor using fewer genes than previous gene signatures. Finally, qRT-PCR and immunohistochemical staining investigations were performed in previously collected fresh frozen tumor tissues from HCC patients and their paracancerous normal tissues, and the results were consistent with the bioinformatics results. We found that LGALS3 not only affected the proliferation and migration ability of HepG2 cells but also affected necroptosis and the expression of inflammatory cytokines. Conclusion: In summary, we established and validated an individualized prognostic profile related to necroptosis to forecast the therapeutic response to immune therapy, which might offer a potential non-apoptotic therapeutic target for HCC patients.
1 January 2025 in International Journal of Medical Sciences
While NUSAP1's association with various tumors is established, its predictive value for prognosis and immunotherapy in lung adenocarcinoma (LUAD) remains unconfirmed. We analyzed Nucleolar Spindle-Associated Protein 1 (NUSAP1) gene expression in TCGA and GTEx datasets and validated it in clinicopathological tissues using qRT-PCR and immunohistochemistry. Additionally, we investigated NUSAP1's relationship with patient prognosis across TCGA and five GEO cohorts. The IMvigor210 cohort was utilized to explore NUSAP1's association with immunotherapy efficacy. Furthermore, single-cell RNA-sequencing data was used to examine the correlation between NUSAP1 and immune cell infiltration. Finally, we analyzed the relationship between NUSAP1 and m6A methylation. NUSAP1 expression was significantly elevated in tumor tissues, correlating with poorer prognosis in LUAD patients. It exhibited a significant correlation with immune cell infiltration in the tumor microenvironment, predominantly expressed in Tprolif cells. LUAD patients with heightened NUSAP1 expression may derive greater benefit from anti-PD-L1 treatment. Additionally, NUSAP1 was tightly linked with m6A methylation. Enrichment analysis revealed its association with key biological functions, including lipid metabolism and cell cycle regulation. Our comprehensive analysis underscores NUSAP1's potential as a prognostic and immunotherapeutic biomarker for LUAD, warranting further investigation.
More than a century ago, William Coley observed that bacterial products could trigger tumor regression, a finding that laid the foundation for cancer immunotherapy despite the era's limited immunological knowledge. Today, we continue to pursue the same fundamental goal: equipping the immune system to recognize and eradicate malignant cells. The advent of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 has profoundly reshaped the therapeutic landscape for numerous malignancies. Yet durable clinical benefit remains limited to a subset of patients, and both primary and acquired resistance pose enduring challenges. This has spurred an intensive search for novel immune checkpoints and robust predictive biomarkers to cancer patients receiving ICIs and find no significant changes in liver attenuation or liver enzyme levels, offering reassuring evidence that these agents may not exacerbate hepatic steatosis or subclinical liver injury-a finding particularly relevant for managing patients with pre-existing metabolic liver disease. These clinical vignettes and systematic reviews underscore the need for a multidimensional evaluation framework that incorporates baseline patient characteristics, dynamic biomarker monitoring, and vigilant assessment of immune-related adverse events.The articles collected in this Research Topic illustrate the breadth and depth of current investigation into novel tumor immune checkpoints and their applications.Looking ahead, several priorities warrant attention. The functional overlap and contextdependent expression of immune regulatory molecules call for systematic combinatorial strategies grounded in mechanistic understanding, potentially pairing novel checkpoint blockade with epigenetic modulators, metabolic inhibitors, or rational vaccine platforms. Translating emerging targets from preclinical validation to clinical deployment will require coordinated efforts, innovative trial designs, and the integration of integrative multi-omics approaches-from genomics and transcriptomics to single-cell analyses-to delineate the interplay among tumor metabolism, immune regulation, and therapeutic response. The continued incorporation of artificial intelligence into diagnostic and predictive pipelines is poised to accelerate progress across these domains. We extend our sincere appreciation to all the authors, reviewers, and the editorial team for their contributions, and hope this collection will serve as a catalyst for further investigation, interdisciplinary collaboration, and ultimately the advancement of effective, personalized immunotherapy for patients with cancer.
Noninvasive and effective methods for early screening of non‐small cell lung cancer (NSCLC) still need to be developed. At present, a reasonable conclusion is that a combination of tumor markers is a superior predictor of screening. Cytokines, as important regulators of cancer development, have great potential for the screening and prognosis of NSCLC. This study screened novel biomarkers related to the early screening and prognosis of NSCLC. In the present study, the biological significance and immunoregulation of interleukin‐24 (IL‐24) were analyzed based on The Cancer Genome Atlas data. Next, 150 serum samples from initially treated patients with NSCLC and 70 controls were collected, and we obtained pathological sections from 60 patients with NSCLC. The ELISA and immunohistochemistry results showed the differential expression of IL‐24 and carbohydrate antigen 125 (CA125). The results show that IL‐24 is an important tumor suppressor in NSCLC that helps to improve the poor prognosis of these patients. A significantly negative correlation between IL‐24 and CA125 levels was also found. Notably, serum IL‐24 levels were significantly negatively correlated with the TNM stage of patients with NSCLC, consistent with an important role for tumor suppressors in NSCLC. The receiver operating characteristic curve analysis showed that a combination of IL‐24 and CA125 was an effective panel for discriminating patients with NSCLC from HD, and individuals with other lung diseases. Serum IL‐24 and CA125 levels were identified as independent prognostic markers for NSCLC. The IL‐24 and CA125 panel exhibited good performance in the screening of NSCLC.